Literature DB >> 24978711

Overexpression of hypoxia-inducible factor-1α is a predictor of poor prognosis in cervical cancer: a clinicopathologic study and a meta-analysis.

Miaoling Huang1, Qing Chen, Jianpeng Xiao, Tingting Yao, Lijuan Bian, Changhao Liu, Zhongqiu Lin.   

Abstract

BACKGROUND: Published data on the prognostic value of hypoxia-inducible factor-1α (HIF-1α) expression in cervical cancer are conflicting and heterogeneous. We aimed to derive a more precise estimation of them.
METHODS: We conducted a clinicopathologic study in 74 patients with early-stage cervical cancer treated through surgery and performed a meta-analysis among patients with cervical cancer of all stages to estimate the prognostic importance of HIF-1α expression for disease-free survival (DFS) and overall survival (OS). Expression of HIF-1α was evaluated through immunohistochemistry.
RESULTS: A positive nuclear expression of HIF-1α was found in 94.6% of all specimens. There were significant associations between HIF-1α expression and International Federation of Gynecology and Obstetrics stage (P = 0.024), tumor size (P = 0.003), and anemia (P = 0.010), respectively. Log-rank tests revealed significant correlations between HIF-1α expression, International Federation of Gynecology and Obstetrics stages, tumor grade, tumor size and DFS/OS, respectively. The multivariate Cox regression analyses revealed HIF-1α overexpression and high tumor grade to be independent predictors for impaired DFS (HIF-1α overexpression: hazard ratio [HR], 2.67; 95% confidence interval [CI], 1.10-6.47; high tumor grade: HR, 5.56; 95% CI, 1.47-21.13) and OS (HIF-1α overexpression: HR, 2.57; 95% CI, 1.06-6.23; high tumor grade: HR, 6.23; 95% CI, 1.49-25.97). The results of 10 studies indicated that HIF-1α overexpression predicted poor DFS (HR, 1.98; 95% CI, 1.22-3.21) and OS (HR, 2.58; 95% CI, 1.86-3.56) for cervical cancer.
CONCLUSIONS: The present clinicopathologic study and meta-analysis showed that HIF-1α overexpression is associated with poor survival of cervical cancer and emphasized the importance of HIF-1α as a predictor for cervical cancer.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24978711     DOI: 10.1097/IGC.0000000000000162

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  17 in total

Review 1.  Hypoxia-Induced Signaling Promotes Prostate Cancer Progression: Exosomes Role as Messenger of Hypoxic Response in Tumor Microenvironment.

Authors:  Gagan Deep; Gati K Panigrahi
Journal:  Crit Rev Oncog       Date:  2015

2.  Similarity in the functions of HIF-1α and HIF-2α proteins in cervical cancer cells.

Authors:  Lixia Jiang; Shaohua Shi; Qiaofa Shi; Huijuan Zhang; Rong Hu; Meizhen Wang
Journal:  Oncol Lett       Date:  2017-08-28       Impact factor: 2.967

Review 3.  The role of hypoxic signalling in metastasis: towards translating knowledge of basic biology into novel anti-tumour strategies.

Authors:  Joaquín Araos; Jonathan P Sleeman; Boyan K Garvalov
Journal:  Clin Exp Metastasis       Date:  2018-08-31       Impact factor: 5.150

4.  Clinicopathological characteristics of gynecological cancer associated with hypoxia-inducible factor 1α expression: a meta-analysis including 6,612 subjects.

Authors:  Yue Jin; Haolu Wang; Xiaowei Ma; Xiaowen Liang; Xin Liu; Yu Wang
Journal:  PLoS One       Date:  2015-05-19       Impact factor: 3.240

5.  Association Between HIF-1 Alpha Gene Polymorphisms and Response in Patients Undergoing Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer.

Authors:  Qing Chen; Wei-Jie Tian; Miao-Ling Huang; Chang-Hao Liu; Ting-Ting Yao; Mei-Mei Guan
Journal:  Med Sci Monit       Date:  2016-09-05

Review 6.  Hypoxia in cervical cancer: from biology to imaging.

Authors:  Heidi Lyng; Eirik Malinen
Journal:  Clin Transl Imaging       Date:  2017-07-10

7.  HER Family Receptors are Important Theranostic Biomarkers for Cervical Cancer: Blocking Glucose Metabolism Enhances the Therapeutic Effect of HER Inhibitors.

Authors:  Olga Martinho; Renato Silva-Oliveira; Fernanda P Cury; Ana Martins Barbosa; Sara Granja; Adriane Feijó Evangelista; Fábio Marques; Vera Miranda-Gonçalves; Diana Cardoso-Carneiro; Flávia E de Paula; Maicon Zanon; Cristovam Scapulatempo-Neto; Marise A R Moreira; Fátima Baltazar; Adhemar Longatto-Filho; Rui Manuel Reis
Journal:  Theranostics       Date:  2017-01-15       Impact factor: 11.556

Review 8.  Interfering with Tumor Hypoxia for Radiotherapy Optimization.

Authors:  Irma Telarovic; Roland H Wenger; Martin Pruschy
Journal:  J Exp Clin Cancer Res       Date:  2021-06-21

9.  Reprogramming energy metabolism and inducing angiogenesis: co-expression of monocarboxylate transporters with VEGF family members in cervical adenocarcinomas.

Authors:  Céline Pinheiro; Eduardo A Garcia; Filipa Morais-Santos; Marise A R Moreira; Fábio M Almeida; Luiz F Jubé; Geraldo S Queiroz; Élbio C Paula; Maria A Andreoli; Luisa L Villa; Adhemar Longatto-Filho; Fátima Baltazar
Journal:  BMC Cancer       Date:  2015-11-02       Impact factor: 4.430

Review 10.  Profile of bevacizumab and its potential in the treatment of cervical cancer.

Authors:  Christine M Fisher; Tracey E Schefter
Journal:  Onco Targets Ther       Date:  2015-11-19       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.